NCI Offers Prostate Cancer Genotyping Predictive IP | GenomeWeb
NEW YORK (GenomeWeb News) - The National Institutes of Health is making a prostate cancer-related genotyping technology available for either exclusive or non-exclusive licensing.
 
The National Cancer Institute’s Medical Oncology Branch is seeking interested research collaborators to develop, evaluate, or commercialize the use of this technology, which is used to predict survival prognoses for prostate cancer patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.